TY - JOUR
T1 - European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility
AU - European Malignant Hyperthermia Group
AU - European Malignant Hyperthermia Group
AU - European Malignant Hyperthermia Group
AU - European Malignant Hyperthermia Group
AU - European Malignant Hyperthermia Group
AU - European Malignant Hyperthermia Group
AU - European Malignant Hyperthermia Group
AU - European Malignant Hyperthermia Group
AU - European Malignant Hyperthermia Group
AU - European Malignant Hyperthermia Group
AU - European Malignant Hyperthermia Group
AU - European Malignant Hyperthermia Group
AU - European Malignant Hyperthermia Group
AU - European Malignant Hyperthermia Group
AU - European Malignant Hyperthermia Group
AU - Hopkins, P. M.
AU - Rüffert, H.
AU - Snoeck, M. M.
AU - Girard, T.
AU - Glahn, K. P.E.
AU - Ellis, F. R.
AU - Müller, C. R.
AU - Urwyler, A.
AU - Bandschapp, O.
AU - Gillies, R.
AU - Glauber, V.
AU - Heytens, L.
AU - Islander, G.
AU - Klingler, W.
AU - Kraft, B.
AU - Krivosic-Horber, R.
AU - Pollock, N.
AU - Schuster, F.
AU - Silva, H.
AU - Sorrentino, V.
AU - Street, N.
AU - Tegazzin, V.
AU - Tzanova, I.
N1 - Publisher Copyright:
© 2015 The Author 2015.
PY - 2015/10
Y1 - 2015/10
N2 - It is 30 yr since the British Journal of Anaesthesia published the first consensus protocol for the laboratory diagnosis of malignant hyperthermia susceptibility from the European Malignant Hyperthermia Group. This has subsequently been used in more than 10 000 individuals worldwide to inform use of anaesthetic drugs in these patients with increased risk of developing malignant hyperthermia during general anaesthesia, representing an early and successful example of stratified medicine. In 2001, our group also published a guideline for the use of DNA-based screening of malignant hyperthermia susceptibility. We now present an updated and complete guideline for the diagnostic pathway for patients potentially at increased risk of developing malignant hyperthermia. We introduce the new guideline with a narrative commentary that describes its development, the changes to previously published protocols and guidelines, and new sections, including recommendations for patient referral criteria and clinical interpretation of laboratory findings.
AB - It is 30 yr since the British Journal of Anaesthesia published the first consensus protocol for the laboratory diagnosis of malignant hyperthermia susceptibility from the European Malignant Hyperthermia Group. This has subsequently been used in more than 10 000 individuals worldwide to inform use of anaesthetic drugs in these patients with increased risk of developing malignant hyperthermia during general anaesthesia, representing an early and successful example of stratified medicine. In 2001, our group also published a guideline for the use of DNA-based screening of malignant hyperthermia susceptibility. We now present an updated and complete guideline for the diagnostic pathway for patients potentially at increased risk of developing malignant hyperthermia. We introduce the new guideline with a narrative commentary that describes its development, the changes to previously published protocols and guidelines, and new sections, including recommendations for patient referral criteria and clinical interpretation of laboratory findings.
KW - CACNA1S
KW - RYR1
KW - diagnosis
KW - excitation-contraction coupling
KW - malignant hyperthermia
KW - malignant hyperthermia susceptibility
KW - skeletal muscle
UR - https://www.scopus.com/pages/publications/84943246453
U2 - 10.1093/bja/aev225
DO - 10.1093/bja/aev225
M3 - Review article
C2 - 26188342
AN - SCOPUS:84943246453
SN - 0007-0912
VL - 115
SP - 531
EP - 539
JO - British Journal of Anaesthesia
JF - British Journal of Anaesthesia
IS - 4
ER -